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Abstract 
Background: Study aim was to evaluate the safety and durability of darunavir/cobicistat (DRV/c) in a real life setting.
Methods: Multicentre prospective cohort study performed in the context of SCOLTA (Surveillance Cohort Long-
Term Toxicity Antiretrovirals). Patients were evaluated at baseline, week 24 and 48. Changes were evaluated using the 
paired t test or signed rank test. The multivariable analysis was performed using a general linear model, after ranking 
of not normally distributed variables.
Results: A total of 249 patients were included, 72 (29%) were in DRV/c-based dual therapies (DT). Hypercholes-
terolemia, HC, (total cholesterol (TC) ≥ 200 mg/dL or low density-C (LDL-C) ≥ 130 or statin use) was present in 121 
(48.6%) and hypertriglyceridemia, (triglycerides (TG) ≥ 200 mg/dl or fibrate use) in 41 (16.5%) patients. Blood lipid 
profile did not change significantly in either the global population or patients with HC. After a median observation 
of 17 months (IQR 13–20), 59 (25.3%) patients discontinued DRV/c, of which 13 were in DT. The durability DT resulted 
higher than that of triple therapy (log-rank test p = 0.01). Main reasons for stopping DRV/c were simplification (15 
patients), adverse events (13 patients), planned discontinuation for treatment initiation with DAA (4 patients), treat-
ment failure (2 patients); death (2 patients), other causes (10 patients). Twenty-six were lost to follow-up.
Conclusions: DRV/c was safe and well tolerated. Dual therapies showed a better profile of tolerability and a longer 
durability compared to triple therapies.
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Background
The first arrival of protease inhibitors (PI) in 1996 [1] has 
been one of the turning points in the history of AIDS. 
For years, PI have been the preferred third agents for 
combined antiretroviral therapies (cART) [2] but, in the 
more recent period, only darunavir (DRV) (boosted with 
either ritonavir or cobicistat) is the preferred PI in first-
line cART, in combination with two nucleos(t)ide reverse 
transcriptase inhibitors (NRTI) in current EACS guide-
lines [3], and similarly, DRV is the preferred PI in certain 
clinical situations in DHHS and Italian guidelines. [4, 5]. 
The PIs remain instead the cornerstone of salvage thera-
pies, in non-adherent patients, both naïve or experienced 
[6, 7]. The novel co-formulation of darunavir/cobicistat 
(DRV/c) constitutes a new step forward towards improv-
ing convenience and adherence without loss of virologi-
cal efficacy. Moreover, DRV/c co-formulation offers the 
possibility of reducing the side effects classically linked 
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to ritonavir boosting use, including multiple drug inter-
actions, metabolic and gastrointestinal effects [8, 9]. 
Clinical trials of DRV/c showed promising results of effi-
cacy and tolerability in both first line [10, 11] and switch 
strategies [12, 13], with high viral response also in expe-
rienced patients with history of previous virological fail-
ures and exposure to multiple antiretroviral classes [10].
Moreover, triple combinations of antiretrovirals have 
been the standard treatment for HIV infection, but the 
recent advent of more potent and safer antiretrovirals has 
renewed the interest for simpler HIV regimens. However, 
besides clinical trials, data on real-life experience with 
DRV/c both in dual or standard triple therapy are still 
scarce, and mainly based on retrospective studies [14, 15] 
or restricted to mono or dual therapies [16].
The aim of the present study is to evaluate DRV/c dura-
bility and tolerability in dual as well as in triple therapy, 
using data from the SCOLTA prospective study cohort, a 
real-life setting.
Materials and methods
The SCOLTA (Surveillance Cohort Long-Term Toxic-
ity Antiretrovirals) project is a multicentre and observa-
tional study, started in 2002, that follows HIV-infected 
people who start a new drug prospectively, with the aim 
of identifying toxicities and adverse events in real-life 
setting.
For the present study, all patients aged > 18 years who 
started DRV/c in the participating centers, in either first 
line or switch strategies, were considered eligible.
Demographic, clinical and laboratory data, includ-
ing CD4+ T-cell count (CD4), HIV-RNA, creatinine 
level and metabolic data such as total cholesterol (TC), 
triglycerides (TG), LDL-cholesterol (LDL), HDL-choles-
terol (HDL), were prospectively collected in anonymous 
form in a central database at the moment of initiation of 
DRV/c and every 24 weeks. For patients experienced to 
antiretroviral treatment, data on the previous antiretro-
virals and cumulative exposure to antiretroviral therapy 
were collected.
Estimated glomerular filtration rate (eGFR) was cal-
culated using Cockroft-Gault equation [17]. Hypercho-
lesterolemia (HC) was defined as TC ≥ 200  mg/dL or 
LDL ≥ 130 or statin use. Hypertriglyceridemia (HT) was 
defined as TG ≥ 200 mg/dl or fibrate use.
Patients were described using frequency for categorical 
variables and mean (standard deviation, SD) or median 
(interquartile range, IQR) for continuous variables. DRV-
containing dual and triple therapy groups were com-
pared using heterogeneity Chi square test (of Fisher’s or 
Mantel-Hanszel test as appropriate), analysis of variance 
or Mann-Withney U test, respectively, as regards base-
line characteristics. Patients were evaluated at baseline 
(T0), week 24 (T1) and week 48 (T2). Change from T0 
was evaluated using the paired t-test for continuous vari-
ables if normally distributed and the signed rank test if 
not. Changes in eGFR, CD4, and lipids at T1 and T2 were 
subsequently compared between patients on dual and on 
triple therapy using analysis of variance or Mann-With-
ney U test, respectively.
Changes in eGFR were also compared in groups of 
patients taking tenofovir disoproxil fumarate (TDF) or 
not as part of their ART regimen, using the analysis of 
variance to perform the between-groups comparison.
The multivariable analysis was performed using a gen-
eral linear model, after ranking of not normally distrib-
uted variables, if any. The durability of DRV/c treatment 
was defined as the time on continuous DRV/c use. The 
discontinuation or changing of other components of the 
ART regimen was not considered in durability analysis. 
Hazard ratio for discontinuation of DRV/c were calcu-
lated from fitting a Cox regression model and durability 
was represented throughout Kaplan–Meier plot. Differ-
ences were considered significant for p values < 0.05.
Grade 3–4 adverse events and treatment interruptions 
were recorded and detailed in the central database when 
they occurred [18]. Data collection started in May 2016, 
and continued till present (last data merger in March 
2019).
The study protocol was approved by the local ethics 
committees of the participating centres and written con-
sent was obtained from all participants.
Results
We identified 249 HIV-infected patients who started 
DRV/c containing antiretroviral regimens. The general 
characteristics of the patients are showed in Table 1.
Among them, 182 were males (73.1%), 235 Caucasian 
(94.4%). Mean age was 48.0 (± 10.4) years, similar in both 
sexes. Nine patients (3.6%) were cART naïve.
Seventy-two (28.9%) were in DRV/c-based dual thera-
pies and 177 (71.1%) in DRV/c triple therapy (Fig.  1); 
76.4% and 77.4% respectively switched to DRV/c from 
regimens already including DRV.
Among them (N = 192 subjects) the median time on 
previous DRV treatment was 26  months (IQR 14–44). 
Follow up at 24 and 48  weeks was available for 239 
(96.9%) and 181 (72.7%) patients, respectively. Sex and 
risk factor for HIV infection were different by groups, as 
well as time on previous PI and ART in general. Patients 
on dual therapy were also more likely hypercholester-
olemic. On the whole, HC was present in 48.6% and HT 
in 16.5% of patients, similar in dual and triple therapy 
groups. At 24 and 48 weeks after DRV/c initiation CD4 
increased, without significant differences between dual 
and triple therapy (Table 2).
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As compared to baseline, eGFR significantly 
decreased at T1 and T2. Comparing eGFR trend in 
groups of patients on tenofovir (122, 49.2%) as poten-
tially kidney-damaging drug we found that eGFR 
change from baseline was more marked in patients 
taking tenofovir than in others: − 9.5 ± 1.6  ml/min 
(p < 0.0001), and − 4.2 ± 1.4  ml/min (p = 0.003), sig-
nificant in the between-groups comparison (p = 0.01). 
At T2, this difference would narrow, and eGFR was 
− 9.1 ± 1.8 and − 7.5 ± 1.5 ml/min respectively, similar 
between groups (p = 0.50).
Blood lipid profile did not change significantly in 
either the global population or patients with HC. No 
difference was found in TC, HDL, TC/HDL and TG 
change between patients in dual or in triple therapy 
(Table  2). Adjusting for factors that were different at 
baseline did not change our findings.
After a median observation of 17 months (IQR 13–20), 
72 (28.9%) patients discontinued DRV/c, of which 16 
(22.2%) were on dual and 56 (31.6%) on triple therapy.
The durability of dual regimens resulted higher than 
that of triple therapies (log-rank test p = 0.01, Fig. 2).
However, after adjusting for age, sex, risk factor for 
HIV acquisition, CDC stage at initiation and years on 
ART, the protective role of dual therapy was no longer 
significant (hazard ratio for interruption 0.70, 95% confi-
dence interval 0.39–1.27, triple regimen as the reference).
Discontinuations due to adverse events were 13 (2 renal, 
3 gastro-intestinal, 1 allergy, 1 asthenia, 3 dyslipidemia, 1 
osteoporosis, 1 central nervous system, 1 undefined), 15 
Table 1 Baseline characteristics of 249 patients enrolled in the DRV/COBI cohort
SD: Standard deviation; PI: protease inhibitors; NNRTI: non nucleoside reverse transcriptase inhibitors; IQR: interquartile range; eGFR: estimated glomerular filtration 
rate
* Mantel–Haenszel Chi square test
** Experienced patients, n = 240
Dual therapy Triple therapy P
N % N %
Enrolled patients 72 28.9 177 71.1
Female 28 38.9 39 22.0 0.007
Risk factor for HIV acquisition
 Sexual 30 41.7 103 58.2
 Intravenous drug use 29 40.3 46 26.0
 Transfusion/vertical/unknown 13 5.6 28 1.1 0.04
Ethnicity
 Caucasian 70 97.2 165 93.2
 Other 2 2.8 12 6.8 0.21
 Naive 1 1.4 8 4.5 0.45
CDC stage
 A 15 20.8 47 26.6
 B 40 55.6 68 38.4
 C 17 23.6 62 35.0 0.59*
HIVRNA > 50 copies/mL at T0** 11 15.5 12 7.1 0.04
Previous regimen including**
 PI 61 85.9 161 95.3 0.01
 NNRTI 15 21.1 4 2.4 < 0.0001
Hypercholesterolemia 44 61.1 77 43.5 0.03
Hypertriglyceridemia 11 15.3 30 16.9 0.67
Mean or median SD or IQR Mean or median SD or IQR
Mean age, SD (years) 50.2 10.8 48.2 10.1 0.17
Mean CD4, SD (cells/mm3) 625 381 581 343 0.37
Median time on PI, IQR (years) 8.8 5.9–11.5 5.8 2.5–10.0 0.001
Median time on NNRTI, IQR (years) 2.4 0.9–4.8 1.6 0.1–5.3 0.12
Median time on ART, IQR (years) 18.1 7.8–21.0 9.0 3.2–17.9 < 0.0001
Mean eGFR, SD (mL/min) 94.2 20.3 96.3 23.6 0.50
Page 4 of 8Taramasso et al. AIDS Res Ther           (2019) 16:21 
discontinued for simplifications or pro-active switches. 
Two patients discontinued DRV/c for treatment failure; 2 
died (1 lung cancer, 1 unknown reason). Four interrupted 
because of drug–drug interactions, 8 for low adherence/
patient’s preference. Twenty-six were lost to follow-up. 
Most adverse events and simplifications occurred in the 
triple regimen group (Table 3).
Discussion
This study investigated the safety and durability profile 
of DRV/c in a large prospective cohort (SCOLTA). Our 
results showed DRV/c was well tolerated and adverse 
events leading to discontinuations occurred in 13 
patients, namely 5% of the study population. In the group 
of patients on triple therapy, simplification was the prin-
cipal cause of discontinuation (14 patients on triple ther-
apy vs. 1 patient on dual therapy). Of note, DRV/c has 
demonstrated low rate of virological failure (2 patients, 
2.8%).
The rate of discontinuations due to adverse events 
was higher than that seen in EMERALD (i.e. 1%) and 
AMBER (i.e. 2%) trials [10, 12], but similar to real-life 
studies on DRV/ritonavir (i.e. 3–5%) [11, 19], suggest-
ing, possibly, a lower threshold of tolerance for adverse 
events, or also a more difficult-to-treat population, in 
the context of real-life studies compared to clinical tri-
als. Regarding the metabolic aspects of DRV safety, 
PI and, in particular, ritonavir-boosted PI, have been 
associated in the past to altered insulin sensitivity and 
unfavourable metabolic profile [20]. However, in a pre-
vious study, the switch from ritonavir to cobicistat was 
followed by a significant reduction in TC, LDL, but 
DTG/DRV/c
10%
RAL/DRV/c
10%
Dual (other)
9%
TDF/FTC/DRV/c
50%
3TC/ABC/DRV/c
17%
Triple (other)
4%
Fig. 1 Antiretroviral therapy drug regimens in patients initiating 
darunavir/cobicistat (DRV/c). 3TC: lamivudine; ABC: abacavir; DRV/c: 
darunavir/cobicistat; DTG: dolutegravir; FTC: emtricitabine; RAL: 
raltegravir; TDF: tenofovir
Table 2 Changes in  estimated glomerular filtration 
rate (eGFR), CD4+ T cell count (CD4), and  lipids at  24 
and 48 weeks after starting darunavir/cobicistat
SD: Standard deviation; SE: standard error; T0: baseline; T1: 24 week follow 
up; T2: 48 week follow up; TC: total cholesterol, TG: triglycerides; HDL: HDL 
cholesterol
* P for change from baseline < 0.05
Dual therapy Triple therapy P 
between groups
Mean SD Mean SD
eGFR mL/min
 T0 94.2 20.3 96.3 23.6
 T1 90.2 19.0 88.7 21.7
 T2 86.7 17.7 87.7 18.6
T1-T0 (mean, SE) − 4.6* 1.8 − 7.6* 1.3 0.19
T2-T0 (mean, SE) − 7.6* 1.9 − 8.5* 1.4 0.71
CD4 cells/mm3
 T0 625.2 381.0 580.6 342.9
 T1 653.3 309.2 641.0 364.4
 T2 712.6 326.0 664.1 365.0
T1-T0 (mean, SE) 18.5 30.5 60.8* 15.6 0.22
T2-T0 (mean, SE) 35.3 26.7 64.2* 19.1 0.38
HDL mg/dL
 T0 51.0 16.6 47.0 14.8
 T1 50.2 15.6 47.9 14.8
 T2 52.8 16.3 47.3 15.2
T1-T0 (mean, SE) − 1.2 1.0 1.2 0.8 0.07
T2-T0 (mean, SE) 1.8 2.2 0.7 1.2 0.62
TC mg/dL
 T0 200.0 47.6 187.3 42.5
 T1 199.4 45.8 190.0 40.8
 T2 204.5 45.3 192.5 46.6
T1-T0 (mean, SE) − 1.2 3.6 3.6 2.3 0.24
T2-T0 (mean, SE) 0.1 5.0 2.4 3.3 0.69
TG mg/dL
 T0 (median, IQR) 128 92–169 124 88–168
 T1 (median, IQR) 133 97–177 111 86–167
 T2 (median, IQR) 145 90–183 120 86–194
T1-T0 (mean, SE) 32.3 31.7 − 5.7 4.4 0.24
T2-T0 (mean, SE) 4.3 8.6 3.3 6.5 0.92
TC/HDL
 T0 4.20 1.34 4.27 1.37
 T1 4.26 1.39 4.25 1.38
 T2 4.11 1.21 4.31 1.29
T1-T0 (mean, SE) 0.07 0.08 − 0.05 0.08 0.31
T2-T0 (mean, SE) − 0.13 0.14 − 0.05 0.09 0.62
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also of HDL, and TG levels in patients with HC [14]. 
In our prospective observation, despite most patients 
were switching from ritonavir boosted PI to DRV/c, we 
did not observe significant change in lipids, even in the 
sub-analysis focused on patients with higher baseline 
triglycerides and cholesterol levels, which were those 
expected to experience the greatest lipid changes [14, 
21]. These results were consistent with previous stud-
ies including a large proportion of patients on ritona-
vir-boosted PI regimens who switched to DRV/c [12, 
16], although lipid changes could have been partially 
confounded by the presence or removal of tenofovir 
disoproxil fumarate (TDF) from the regimen after the 
switch, with consequent lost of its lipid lowering effect 
[22]. Another issue related to the use of cobicistat is its 
inhibition of the tubular secretion of creatinine, owing 
to an expected apparent decrease of average 10  mL/
min in the eGFR [23]. In the SCOLTA cohort, a reduc-
tion of eGFR was found, more evident after 6  months 
in people taking tenofovir disoproxil fumarate (TDF). 
A worse eGFR trend in course of TDF associated to 
cobicistat was also noticed in other studies [10, 12], 
Fig. 2 Durability of dual and triple combined antiretroviral regimens containing darunavir/cobicistat (DRV/c). Patients were censored when 
stopping DRV/c
Table 3 Reasons for interruption of darunavir/cobicistat
Dual therapy Triple therapy Total
N = 72 % N = 177 % N = 249 %
Adverse events 1 1.4 12 6.8 13 5.2
Simplification/proactive switch 1 1.4 14 7.9 15 6.0
Patient’s preference/low adherence 2 2.8 6 3.4 8 3.2
Therapeutic failure 2 2.8 0 0.0 2 0.8
Death 0 0.0 2 1.1 2 0.8
Drug-drug interaction 1 1.4 3 1.7 4 1.6
Other reasons 1 1.4 1 0.6 2 0.8
Lost to follow-up 8 11.1 18 10.2 26 10.4
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suggesting the possibility of a TDF-boosting effect of 
cobicistat, also previously hypothesized for ritonavir 
[24, 25]. Indeed, DRV/c is expected to increase TDF 
plasma concentration due to P-glycoprotein inhibi-
tion, although there are currently inadequate data to 
determine whether TDF and DRV/c co-administration 
could be associated with highest risk of renal toxicity 
[26]. However, the eGFR decline at T2 was similar in 
patients who were tacking TDF or not.
Finally, two out of 249 patients (< 1%), experienced 
virological failure in the observation period (median 
17 months), similar or even lower when compared with 
previous data [10, 12, 19].
Despite this, the total discontinuation rate was unex-
pectedly high, with 29% of the study population who 
stopped DRV/c, often for reasons other than adverse 
events, namely treatment simplifications, proactive 
switches or drug interactions. Those data could poten-
tially be different with the arrival of the new single tab-
let formulation of DRV/c and tenofovir alafenamide 
(TAF), that could bring to lower rate of simplification 
thanks to the advantage of a single-pill regimen and the 
excellent safety profile of its TAF component [10, 12, 
27]. On the other hand, the ageing of the HIV infected 
population and the desire of minimizing the possible 
metabolic effects of ART could be another important 
reason for proactive PI withdrawal from the regimen 
[28].
Of note, dual therapies showed a lower number of 
discontinuations due to any cause and also to adverse 
events. A possible explanation could be that the current 
direction of the modern HIV care is an optimization and 
a customization of the treatment, with dual therapies 
based on PI being tailored on patients needs. [29] On 
the contrary, PI triple therapy might be more generally 
prescribed to anyone, but demonstrated lower durabil-
ity [30, 31], mainly for simplification or tolerability issues. 
Indeed, PIs have now many competitors in the modern 
ART scenario, including integrase inhibitors and rilpiv-
irine, characterized by good tolerability and high durabil-
ity [32–35]. In fact, despite DRV/c can be used in both 
naïve and experienced patients, our results showed as, 
in real life, it was mainly used in subjects switching from 
antiretroviral treatments already containing PI.
The present study has some limitations. First, a large 
number of heterogeneous ART regimens were included, 
comporting a possible confounding role of the accompa-
nying backbones, if any. Second, SCOLTA protocol does 
not collect genotypic resistance data, and thus a further 
characterization of the study population and, in particu-
lar, of patients taking dual regimens, was not possible. 
Third, 48 weeks follow up was not available for a part of 
patients, limiting the power of some results.
Conclusions
To our knowledge, this study is one of the largest pro-
spective studies available to date on DRV/c use in a 
real-life context. The study included a large number 
of patients with a long history of past antiretroviral 
therapy, allowing the prospective evaluation of DRV/c 
safety and efficacy in a complex study population, likely 
similar to the one in care, and in treatment with PI, in 
clinical settings. DRV/c was safe and well tolerated in 
SCOLTA cohort and only 2 patients discontinued it due 
to virological failure. Dual therapies showed a better 
profile of tolerability and a longer durability compared 
to triple therapies.
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